结肠癌及其引流淋巴结的形态研究附181例手术切除标本分析

结肠癌的发病率在欧美一些国家常居首位,在我国,约占全部恶性肿瘤发病率之第三位至第七位。本文除分析结肠癌一般形态特征外,着重分析引流淋巴结的形态特征、转移情况及其与预后的相互关系。材料及方法本文分析中国医学科学院肿瘤研究所病理科自1958至1969年共12年间手术切除的结肠直肠癌181例。资料不全或术前放疗、术前化疗的病例不包括在本组内。全部病例均随诊5年以上,失随诊者一律作死亡计。手术标本送至本科后,洗净血迹,沿肠壁肿瘤对侧正常肠壁     

纤维蛋白溶解动力学检测及应用

目的探讨建立一种简便、快捷检测人体纤维蛋白溶解(纤溶)功能的新方法。方法利用UV2000型分光光度计联接微机,自动扫描观测并记录血液凝固及溶解的光密度动态图形改变过程,并以此了解血浆抗、促纤溶的能力。结果初步建立了正常人纤溶动力学分析参数,确定了20U/ml尿激酶为最适试验浓度,检测22例正常人,27例急性髓细胞白血病患者纤溶动力学及纤溶酶原含量,显示患病组较正常组差异有显著意义(P<0.05,P<0.01),重复性试验显示该方法的变异系数为(5.42±1.51)%,并可同步测定血浆纤维蛋白原浓度。结论据结果可认为该方法稳定可靠,可为临床提供动态、直观、多参数的实验资料,在评价血浆抗、促纤溶能力、治疗监测、药物选择、浓度调节等方面均有价值。     

新形势下社会共治保障医院安全秩序的思考

近年来, 我国出台了多部加强医院安全秩序管理的法律法规, 制度体系逐步完善, 但其中有关医疗机构的管理要求不易落实, 医院内部压力较大, 存在外部支撑不足的情况。本研究基于社会共治的视角, 探讨我国医院安全秩序管理相关政策发展脉络, 从政府、医院、社会组织三方面归纳总结保障医院安全秩序的工作实践经验, 对警医联动处置机制不健全、技防措施落实不到位、医患矛盾跟进调解处置不及时、配套政策不完善等问题进行了分析, 提出保障医院安全秩序长效机制相关建议。     

��������Ѫ˨�γɻ��Ƽ�����

血栓形成是肿瘤患者的常见并发症之一[1-3].肿瘤患者的血栓多为静脉血栓,据一项大宗病例研究报道,不同类型恶性肿瘤患者中静脉血栓形成(VTE)的发生率为2.74%～12.10%,而并发VTE可能导致癌症患者死亡的发生率增加2～8倍[1,4-8].     

Fribrinolysis Kinetics and Its Application

A new, convenient, and rapid method for kinetic measurement of human fibrinolysis was established. The alteration of absorbance (A) in the process of blood coagulation and lyses was auto-matically scanned and recorded using a UV2000 spectrophotometer connected to a computer. The parameters of human fibrinolysis kinetics were established. Urokinase at 20 U/mL was the optimal concentration used. There was significant difference in fibrinolysis kinetics and plasma plasminogen concentration between 22 normal subjects and 27 patients with acute myeloblastic leukemia (P<0.05 and <0.01 respectively). The coefficience of variation was (5.24±1.51)%. This method could also be used to measure the plasma fibrinogen concentration at the same time. It was concluded that this method was stable and was capable of providing dynamic, direct experimental data and multipareme-ters for clinicians. It was also valuable in evaluating the anti- and pro-fibrinolytic capcity of patients' plasmas, allowing for monitoring of therapy, choice of drugs and adjustment of drug concentrations.     

军队医院加强医德建设的探讨

军队医院加强医德建设的探讨解放军１５３医院（４５００６５）尹曦华，刘振邦，胡豫生，翟鸿雁医院精神文明建设的中心任务，是培养高尚的医德医风，保证优质的医疗服务，它是医院的灵魂，卫生事业的生命。这个高洁的灵魂，珍贵的生命，已受到不同程序地污染，医德医风建...     

肺炎性假瘤(文献综述)

肺炎性假瘤是一种较为罕见的肺实质内瘤样增生病变。临床及X线表现易与恶性肿瘤相混淆,病理标本肉眼检查酷似真性肿瘤,显微镜下形态结构复杂,在缺乏经验的情况下,又易于误认为是各种良恶性肿瘤。根据多数资料研究表明,本病变组织形态的本质是炎症增生或与炎症结局相关的一系列较为复杂的病变。由于严重地影响到患者的处理措施,有必要对本病变的临床病理特征作一综述,以供有关同志参考。     

反复咖啡色尿伴腹痛、周围神经及精神症状

1　病史摘要患者 ,女 ,2 8岁 ,已婚。因“反复咖啡色尿伴腹痛、周围神经及精神症状 3个月”入院。患者于 2 0 0 0年 9月偶然发现尿色加深 ,呈咖啡色 ,晨起及午睡后较重 ,无其它不适 ,次日消失。 1 0月 1 8日晨起再次出现咖啡色尿 ,伴阵发性脐周绞痛、腰部胀痛 ,无恶心、呕吐及腹泻 ,遂来我院就诊。查血常规 :WBC4.4× 1 0 9/L,HGB76g/L,PLT1 1 2× 1 0 9/L;网织红细胞比值 0 .0 0 7;尿常规 :UBG+ +、BIL + ;PNH全套 (包括 Ham′s试验、热溶血试验、糖水试验、蛇毒因子溶血试验、rous试验 )及 Coombs试验均阴性 ;骨髓细胞学及骨髓…     

Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma

In this study,we administered a modified schedule of weekly intravenous Bortezomib at 1.6 mg/m 2 with dexamethasone(BD) and compared it to the standard 1.3 mg/m 2 twice-weekly BD regimen in Chinese patients with newly diagnosed multiple myeloma(MM).We assessed the difference in efficacy,safety profile and survival between the once-weekly and twice-weekly cohorts(13 vs.24 patients).The over response rate was similar with both arms of the study,being 77% in the once-weekly schedule and 74.9% in the twice-weekly schedule(P=0.690).The median overall survival was not reached in either schedule.Also,the median progression-free survival and duration of response of the once-weekly schedule did not significantly differ from those of the twice-weekly schedule(8 months vs.10 months,P=0.545 and 6 months vs.7 months,P=0.467 respectively).Peripheral sensory neuropathy and grade 3/4 hematologic toxic effects were more frequently reported in the twice-weekly schedule than the once-weekly schedule,but there was no statistically significant difference.This preliminary experience in Chinese patients with newly diagnosed MM indicated that once-weekly infusion of Bortezomib plus dexamethasone may improve safety without affecting outcome.